Biotech Drug Report Generated Jul 2, 2026

TN-401

TNYA·Tenaya Therapeutics, Inc.

MIXED

Drug Impact Rating5/10

Trial Phase: Phase 1b/2
Time to Market: 4-6 years (Phase 1b/2; no pivotal or registrational trial yet initiated)
Why 5/10: The next catalyst is additional interim data from the RIDGE-1 Phase 1b/2 trial (Cohort 2 one-year and Cohort 1 two-year follow-up) expected in H2 2026. TN-401 is a major pipeline asset but not the sole value driver (TN-201 for HCM is the lead program), and these are Phase 1b efficacy/safety updates rather than a registrational or PDUFA binary — so impact is moderate at 5.

Actionable Insight MIXED

Watch for additional RIDGE-1 interim data in H2 2026, which will show durability of the arrhythmia reduction seen so far and expansion to more patients. Also track Rocket Pharma's competitive PKP2 gene therapy RP-A601 (RMAT designation) — a head-to-head differentiation may emerge. The stock (~$0.79) trades at a deep discount to the analyst mean price target of $4.00, reflecting both promise and early-stage risk.

Price Chart

Loading chart...

Executive Summary

TN-401 is an AAV9-based gene therapy from Tenaya Therapeutics (TNYA) for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), a genetic heart condition causing dangerous arrhythmias and sudden cardiac death. It is in a Phase 1b/2 dose-escalation trial (RIDGE-1) with encouraging early data: a mean 64% reduction in arrhythmia burden across 6 patients with no dose-limiting toxicities. TN-401 has FDA Orphan Drug and Fast Track designations. The main risk is direct competition from Rocket Pharmaceuticals' RP-A601 (same target, Phase 1, with RMAT designation) and the early stage of development. Tenaya has adequate cash into H2 2027 and a diversified pipeline led by TN-201 for hypertrophic cardiomyopathy. The stock trades near $0.79, far below the analyst mean target of $4.00, reflecting significant early-stage risk but also meaningful upside if TN-401 data continue positive.

How It Works

TN-401 delivers a working copy of the PKP2 gene directly into heart muscle cells using a harmless virus shell (AAV9) as a delivery vehicle. In patients with PKP2-associated ARVC, the inherited faulty PKP2 gene causes life-threatening heart rhythm problems and structural damage. TN-401 aims to fix the root cause with a one-time intravenous infusion by producing the missing protein that holds heart cells together, potentially stopping the disease progression.

Trial Status

The RIDGE-1 Phase 1b/2 trial (NCT06228924) is actively enrolling in the US and UK. As of April 2026, 6 patients across two dose cohorts (3E13 vg/kg and 6E13 vg/kg) have been dosed with follow-up ranging from 20 to 52 weeks. Positive interim data from Cohorts 1 and 2 was presented at ASGCT in May 2026 showing mean 64% reduction in premature ventricular contractions and favorable safety. Additional cohort data (1-year Cohort 2, 2-year Cohort 1) expected in H2 2026.

The Two-Sided Case

▲ Bull Case5

Early clinical data show a clear signal: mean 64% reduction in PVC arrhythmia burden across 6 patients at both dose levels (3E13 and 6E13 vg/kg), with no dose-limiting toxicities — a strong de-risking for a Phase 1 gene therapy (source: BioSpace May 15, 2026).

FDA Orphan Drug and Fast Track designations plus EMA PRIME designation signal regulatory support and potential accelerated pathways (source: BioSpace May 15, 2026 press release).

Target market is large and underserved: PKP2 mutations affect ~40% of ARVC patients — over 70,000 people in the US alone — with no disease-modifying treatments currently approved (source: Tenaya Therapeutics company website).

Alnylam partnership ($10M upfront, up to $1.13B milestones) validates Tenaya's cardiovascular platform and extends cash runway, reducing dilution risk near-term (source: GlobeNewswire March 5, 2026).

Analyst consensus is strongly bullish: 13 analysts with 4 strong buy, 9 buy, 1 hold; mean price target $4.00 vs ~$0.79 current — implying ~400% upside.

▼ Bear Case5

Direct competitor: Rocket Pharmaceuticals' RP-A601 targets the exact same PKP2-ACM indication with an AAV-based gene therapy and has already received FDA RMAT (Regenerative Medicine Advanced Therapy) designation, potentially leapfrogging TN-401 (source: BusinessWire July 17, 2025).

TN-401 is still very early (Phase 1b, 6 patients as of April 2026 data cut) — durability, dosing optimization, and larger-sample safety/efficacy are unproven; gene therapy has historically struggled with cardiac delivery.

Tenaya has a history of clinical holds; TN-201 (the lead program) experienced a clinical hold in late 2025 that drove the stock down ~39% in a single day.

The company burned ~$90.6M in 2025 and had only $80.9M cash at Q1 2026 end — though Alnylam's $10M upfront helps, another dilutive offering is a real risk before H2 2027 runway.

Stock is already down ~66% from its 52-week high of $2.35 — reflecting market skepticism about early-stage gene therapy risk despite positive data.

Upcoming Catalysts

Additional interim data from RIDGE-1 Phase 1b/2 (1-year Cohort 2 and 2-year Cohort 1 follow-up) expected H2 2026.
Potential regulatory alignment discussions on TN-401 development pathway later in 2026.
TN-201 (lead program) MyPEAK-1 Phase 1b/2 data readouts in 2026 — positive readouts could lift the entire pipeline's credibility.
Q2 2026 earnings report expected ~August 2026 — financial updates and pipeline guidance.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Tenaya Therapeutics, Inc. 8-K TNYA ·Originating report

Sources · 10

Hover a chip for the title

1 tenayatherapeutics.com2 biospace.com3 globenewswire.com4 biospace.com5 businesswire.com6 biospace.com7 globenewswire.com8 globenewswire.com9 tenayatherapeutics.com10 tipranks.com